Who are PIBRENTASVIR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mavyret, Zepatier, Daklinza, Elbasvir and Grazoprevir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pibrentasvir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PIBRENTASVIR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PIBRENTASVIR (PIBRENTASVIR) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis C Virus NS5A Inhibitor [EPC].

marketed Hepatitis C Virus NS5A Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

PIBRENTASVIR (PIBRENTASVIR).

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PIBRENTASVIR TARGET	PIBRENTASVIR		marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
Mavyret	GLECAPREVIR	AbbVie	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2017-01-01
Zepatier	ELBASVIR	Merck & Co.	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]		2016-01-01
Daklinza	DACLATASVIR	Bristol-Myers Squibb	marketed	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	2015-01-01
Elbasvir and Grazoprevir	Elbasvir and Grazoprevir	University Hospital, Toulouse	marketed	Hepatitis C Virus NS5A Inhibitor [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-07-24 — Zepatier · 7973040 · US
2030-06-10 — Mavyret · 10039754 · US
2030-06-10 — Mavyret · 10028937 · US
2030-11-06 — Mavyret · 9586978 · US
2030-12-10 — Mavyret · 10039754*PED · US
2030-12-10 — Mavyret · 10028937*PED · US
2031-05-04 — Zepatier · 8871759 · US
2031-05-06 — Mavyret · 9586978*PED · US
2032-01-19 — Mavyret · 8648037 · US
2032-05-18 — Mavyret · 8937150 · US
2032-07-19 — Mavyret · 8648037*PED · US
2032-11-18 — Mavyret · 8937150*PED · US
2034-03-14 — Mavyret · 11484534 · US
2034-03-14 — Mavyret · 10286029 · US
2034-09-14 — Mavyret · 10286029*PED · US
2034-09-14 — Mavyret · 11484534*PED · US
2035-05-08 — Mavyret · RE48923 · US
2035-06-05 — Mavyret · 9321807 · US
2035-11-08 — Mavyret · RE48923*PED · US
2035-12-05 — Mavyret · 9321807*PED · US
2036-06-24 — Mavyret · 11246866 · US
2036-12-24 — Mavyret · 11246866*PED · US

Sponsor landscape (Hepatitis C Virus NS5A Inhibitor [EPC] class)

· 1 drug in this class
AbbVie · 1 drug in this class
Merck & Co. · 1 drug in this class
University Hospital, Toulouse · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PIBRENTASVIR — Competitive Intelligence Brief. https://druglandscape.com/ci/pibrentasvir. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing